# Vancomycin

> Glycopeptide antibiotic for serious Gram-positive infections including MRSA.

Source: https://peptides.cafe/peptide/vancomycin
Category: Glycopeptide · Infectious Disease
Tag: FDA-Approved · Antibiotic

## Mechanism
Tricyclic glycopeptide that binds the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking cell wall cross-linking in Gram-positive bacteria.

## Research areas
- MRSA infections
- C. difficile colitis (oral)
- Enterococcal infections

## Common research protocols
- IV systemic: 15–20 mg/kg IV every 8–12h; AUC-based therapeutic monitoring.
- C. diff (oral): 125 mg PO four times daily for 10 days.

## Study summaries
- "Vancomycin AUC vs trough monitoring" — AJHP (2020): Updated consensus guidelines recommend AUC-guided dosing for MRSA.

## Considerations
- FDA-approved.
- Nephrotoxicity, infusion reactions ('red man syndrome').

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.